Skip to main content


Fig. 5 | Breast Cancer Research

Fig. 5

From: Simultaneous blockade of IL-6 and CCL5 signaling for synergistic inhibition of triple-negative breast cancer growth and metastasis

Fig. 5

Model of crosstalk between triple negative breast cancer (TNBC) and lymphatic endothelial cells (LECs). In TNBC, secreted IL-6 from TNBC cells binds to IL-6 receptor in LECs, which enhances CCL5 secretion by activating the STAT3 signaling pathway in LECs. The interaction of CCL5 and CCR5 consequently promotes TNBC tumor growth and metastasis. Therefore, maraviroc and tocilizumab are potential therapeutic drugs to inhibit TNBC tumor growth and metastasis

Back to article page